TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 23534020
Drug: MDPB-free self-etching
Approvals — FDA: no, EMA: no, PMDA: no
Description: MDPB-free self-etching primer with fluoride-containing bonding agent
Study: 19762153
Drug: Ibuprofen 600mg
Normalized name: IBUPROFEN 600MG TAB
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ibuprofen 600mg
Study: 11768323
Drug: Ibuprofen 1200mg
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ibuprofen 1200mg
Study: 27025240
Drug: Aromatase inhibitor
Normalized name: Aromatase inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aromatase inhibitor letrozole (Lz; 2.5 mg/day; n = 16)
Study: 21136235
Drug: Self-management program
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-management program FIBS (six modules including information about fatigue and behavioral therapy strategies)
Study: 7485885
Drug: Rectal diclofenac
Normalized name: diclofenac Rectal Suppository
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rectal diclofenac 100 mg
Study: 22980293
Drug: Intramyocardial injections
Normalized name: ALCOHOL 80 mL in 100 mL INTRAEPICARDIAL LIQUID [80% Alcohol Hand Sanitizer]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramyocardial injections of autologous bone-marrow derived mesenchymal stromal cells (MSCs)
Study: 16444382
Drug: Trimethoprim‐sulfamethoxazole (800/160
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trimethoprim‐sulfamethoxazole (800/160 mg/day, 5 days a week)
Study: 12445024
Drug: Single 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single 1 h infusion of E7070
Study: 12445024
Drug: Daily 1
Normalized name: Beauty 360 Daily 1.2% Moisturizing Topical Lotion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily 1 h infusion of E7070 for 5 days
Study: 15934131
Drug: Monthly telephone
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Monthly telephone contact
Study: 12364304
Drug: Exercise therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exercise therapy plus telephone contact
Study: 30932787
Drug: Crude palm
Normalized name: Palm Oil
DrugBank: Palm oil (DB14377)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Crude palm oil fortified cookies (providing 2152 μg of β-carotene)
Study: 30342554
Drug: Dexamethasone (DXM)
Normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexamethasone (DXM) therapy - 16 mg per day (8 mg twice daily, days 1 to 4), halved every 3 days until 0.5 mg a day on day 19, stopped on day 20.
Study: 26407272
Drug: bivalent rLP2086
Normalized name: L1 protein, human papillomavirus type 16 vaccine
DrugBank: Human papillomavirus type 16 L1 capsid protein antigen (DB10301)
Approvals — FDA: no, EMA: no, PMDA: no
Description: bivalent rLP2086 (3 doses)
Study: 26407272
Drug: bivalent rLP2086
Normalized name: L1 protein, human papillomavirus type 16 vaccine
DrugBank: Human papillomavirus type 16 L1 capsid protein antigen (DB10301)
Approvals — FDA: no, EMA: no, PMDA: no
Description: bivalent rLP2086 (2 doses)
Study: 26407272
Drug: bivalent rLP2086
Normalized name: L1 protein, human papillomavirus type 16 vaccine
DrugBank: Human papillomavirus type 16 L1 capsid protein antigen (DB10301)
Approvals — FDA: no, EMA: no, PMDA: no
Description: bivalent rLP2086 (2 or 3 doses)
Study: 20465648
Drug: 20mg isotretinoin,
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20mg isotretinoin, 3 times per week, nightly moisturizer, and daily sunscreen for three months
Study: 18022044
Drug: Stepped-care intervention
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stepped-care intervention group (12 weeks of optimized antidepressant management followed by six sessions of a pain self-management program)
Study: 12551867
Drug: L-arginine infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-arginine infusion (0.125 g/min) for 120 minutes
Study: 12551867
Drug: Saline infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline infusion for 120 minutes
Study: 10778516
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose (2 vials over 1 hour, followed by 2 vials over 4 hours, repeated 4 hourly until clotting parameters normalized and then 2 vials as infusion over 24 hours)
Study: 10778516
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose (2 vials over 1 hour, followed by 1 vial over four hours, repeated 4 hourly until clotting parameters normalized and then 1 vial as infusion over 24 hours)
Study: 8657463
Drug: Scanning started
Normalized name: venetoclax
DrugBank: Venetoclax (DB11581)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Scanning started at 80% of the contrast injection time
Study: 8657463
Drug: Scanning started
Normalized name: venetoclax
DrugBank: Venetoclax (DB11581)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Scanning started at 100% of the contrast injection time
Study: 8657463
Drug: Scanning started
Normalized name: venetoclax
DrugBank: Venetoclax (DB11581)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Scanning started at 150% of the contrast injection time
Study: 2050170
Drug: Clomipramine (25‐50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clomipramine (25‐50 mg t.i.d.)
Study: 2050170
Drug: Alprazolam (0.25‐0.75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alprazolam (0.25‐0.75 mg t.i.d.)
Study: 6353430
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg feprazone 3-times a day
Study: 6353430
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg feprazone twice a day
Study: 31486072
Drug: Treatment as
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment as usual or wait-list control (n = 221)
Study: 29786898
Drug: Modified Prolonged
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modified Prolonged Exposure (mPE) therapy for PTSD
Study: 29786898
Drug: Non-trauma-focused comparison
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-trauma-focused comparison treatment
Study: 27273910
Drug: Free lutein
Approvals — FDA: no, EMA: no, PMDA: no
Description: Free lutein (10 mg daily for 3 months)
Study: 27273910
Drug: Lutein esters
Normalized name: lutein esters
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lutein esters (20 mg daily for 3 months, equivalent to 10 mg of free lutein)
Study: 24287601
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose of siltuximab
Study: 24287601
Drug: High doses
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High doses of siltuximab (predicted)
Study: 19874316
Drug: Side effects
Normalized name: cured fat, pork side bacon
Approvals — FDA: no, EMA: no, PMDA: no
Description: Side effects of active treatment
Study: 9499103
Drug: Combination antiretroviral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination antiretroviral therapy
Study: 18086590
Drug: PUVA monotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PUVA monotherapy
Study: 30267277
Drug: CO2 laser
Approvals — FDA: no, EMA: no, PMDA: no
Description: CO2 laser irradiation (L)
Study: 30267277
Drug: Fluoride treatment
Normalized name: 60 Second 1.23% Fluoride Treatment Dental Gel
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fluoride treatment (F)
Study: 30267277
Drug: Combined fluoride
Normalized name: Hydrogen fluoride
DrugBank: Hydrogen fluoride (DB11072)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined fluoride and laser treatment (FL)
Study: 30267277
Drug: No treatment,
Approvals — FDA: no, EMA: no, PMDA: no
Description: No treatment, control (C)
Study: 22474057
Drug: B vitamins
Normalized name: B-50 Hi Potency B Vitamins
Approvals — FDA: no, EMA: no, PMDA: no
Description: B vitamins (2 mg folic acid, 25 mg vitamin B(6), 500 μg vitamin B(12))
Study: 14991555
Drug: Lactulose syrup
Normalized name: Lactulose
DrugBank: Lactulose (DB00581)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Lactulose syrup (routine administration twice daily)
Study: 14991555
Drug: Standard care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard care (laxative on indication)
Study: 9920062
Drug: GH replacement
Approvals — FDA: no, EMA: no, PMDA: no
Description: GH replacement therapy (3 or 6 microg/kg x day, s.c.) for 3 months
Study: 2123791
Drug: Pravastatin 5
Normalized name: pravastatin 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pravastatin 5 mg b.d. for 8 weeks followed by 10 mg b.d. for 8 weeks (Group I)
Study: 2123791
Drug: Pravastatin 10
Normalized name: pravastatin 10 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pravastatin 10 mg b.d. for 8 weeks followed by 20 mg b.d. for 8 weeks (Group II)
Study: 6127780
Drug: KWD 2131
Approvals — FDA: no, EMA: no, PMDA: no
Description: KWD 2131 (beta-adrenoceptor stimulant)
Study: 25674699
Drug: Citrulline-Malate (CM)
Normalized name: citrulline malate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Citrulline-Malate (CM) 8 g
Study: 23092310
Drug: Visual aids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Visual aids depicting multimodal treatment options for colorectal cancer
Study: 23092310
Drug: Intensive-treatment option
Normalized name: Head & Shoulders Intensive Treatment
DrugBank: Selenium Sulfide (DB00971)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive-treatment option with clear survival benefit
Study: 23092310
Drug: Milder treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Milder treatment option without survival benefit
Study: 23092310
Drug: Equally intense
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Equally intense treatment options with different timing (neoadjuvant vs. adjuvant) without survival benefit
Study: 17516768
Drug: Alcohol (0.70
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alcohol (0.70 g/kg)
Study: 11228365
Drug: Edmonston-Zagreb (EZ)
Normalized name: measles virus vaccine live, Enders' attenuated Edmonston strain / mumps virus vaccine live, Jeryl Lynn strain / rubella virus vaccine live (Wistar RA 27-3 strain) / varicella-zoster virus vaccine live (Oka-Merck) strain Injection [ProQuad]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Edmonston-Zagreb (EZ) vaccine, two doses at 6 and 9 months
Study: 11228365
Drug: Edmonston-Zagreb (EZ)
Normalized name: measles virus vaccine live, Enders' attenuated Edmonston strain / mumps virus vaccine live, Jeryl Lynn strain / rubella virus vaccine live (Wistar RA 27-3 strain) / varicella-zoster virus vaccine live (Oka-Merck) strain Injection [ProQuad]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Edmonston-Zagreb (EZ) vaccine, one dose at 9 months
Study: 11228365
Drug: Schwarz (SW)
Normalized name: measles virus vaccine live, attenuated Schwarz strain / mumps virus vaccine live, Jeryl Lynn strain / rubella virus vaccine live (Wistar RA 27-3 strain) Injection [Priorix]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Schwarz (SW) vaccine, two doses at 6 and 9 months
Study: 11228365
Drug: Schwarz (SW)
Normalized name: measles virus vaccine live, attenuated Schwarz strain / mumps virus vaccine live, Jeryl Lynn strain / rubella virus vaccine live (Wistar RA 27-3 strain) Injection [Priorix]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Schwarz (SW) vaccine, one dose at 9 months
Study: 11228365
Drug: Edmonston-Zagreb (EZ)
Normalized name: measles virus vaccine live, Enders' attenuated Edmonston strain / mumps virus vaccine live, Jeryl Lynn strain / rubella virus vaccine live (Wistar RA 27-3 strain) / varicella-zoster virus vaccine live (Oka-Merck) strain Injection [ProQuad]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Edmonston-Zagreb (EZ) vaccine, second dose
Study: 11228365
Drug: Schwarz (SW)
Normalized name: measles virus vaccine live, attenuated Schwarz strain / mumps virus vaccine live, Jeryl Lynn strain / rubella virus vaccine live (Wistar RA 27-3 strain) Injection [Priorix]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Schwarz (SW) vaccine, second dose
Study: 9140636
Drug: Intravenous sedation
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous sedation (combination of haloperidol and diazepam, usually 20 mg of each)
Study: 7957410
Drug: 200 micrograms
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 micrograms inhaled oxitropium bromide (OB)
Study: 7957410
Drug: 200 micrograms
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 micrograms inhaled fenoterol (F)
Study: 7957410
Drug: 400 micrograms
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 micrograms inhaled fenoterol (F)
Study: 1827007
Drug: Isradipine (1.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isradipine (1.25 mg twice daily, increased to 2.5 mg if necessary)
Study: 1827007
Drug: Captopril (12.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Captopril (12.5 mg twice daily, increased to 25 mg if necessary)
Study: 1827007
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of Isradipine and Captopril
Study: 968036
Drug: External irradiation
Normalized name: CATHETER,EXTERNAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: External irradiation treatment with total 1,500 rad mid-pelvic dose delivered on five consecutive days
Study: 30826492
Drug: SSRI +
Approvals — FDA: no, EMA: no, PMDA: no
Description: SSRI + vortioxetine (10–20 mg/day)
Study: 30826492
Drug: vortioxetine (10–20
Approvals — FDA: no, EMA: no, PMDA: no
Description: vortioxetine (10–20 mg/day) + placebo
Study: 30826492
Drug: vortioxetine (10–20
Approvals — FDA: no, EMA: no, PMDA: no
Description: vortioxetine (10–20 mg/day)
Study: 17489805
Drug: High-dose botulinum
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose botulinum toxin A (BTX‐A)
Study: 17489805
Drug: Low-dose botulinum
Normalized name: Clostridium botulinum
DrugBank: Clostridium botulinum (DB14223)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-dose botulinum toxin A (BTX‐A)
Study: 16189994
Drug: Food purchased
Normalized name: ALLERGENIC EXTRACT, FOOD, WHEAT
DrugBank: Wheat (DB10579)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Food purchased from a village with < 10 microg/l arsenic in irrigation water
Study: 16189994
Drug: Food purchased
Normalized name: ALLERGENIC EXTRACT, FOOD, WHEAT
DrugBank: Wheat (DB10579)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Food purchased from markets in the study village with > 100 microg/l arsenic in irrigation water
Study: 11914107
Drug: alpha-tocopherol (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: alpha-tocopherol (100 mg/day)
Study: 11914107
Drug: alpha-carotene +
Normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: alpha-carotene + beta-carotene (15 mg/day)
Study: 9860093
Drug: Dual-cured resin
Normalized name: Benzoin resin
DrugBank: Benzoin resin (DB11222)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dual-cured resin composite luting agent
Study: 9860093
Drug: Chemically cured
Normalized name: Cocci-Cure C for Calves
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemically cured resin composite luting agent
Study: 2673340
Drug: 150 mg
Normalized name: pectin 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg ethinyloestradiol gel
Study: 652210
Drug: Laminaria tents
Normalized name: Laminaria digitata preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Laminaria tents used as an adjunct to labor induction
Study: 31373615
Drug: Screening group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Screening group (tested for anti-EBV antibodies)
Study: 25881456
Drug: Telmisartan treatment
Normalized name: Telmisartan
DrugBank: Telmisartan (DB00966)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Telmisartan treatment group (80 mg per day, once daily)
Study: 25881456
Drug: SG treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: SG treatment group (5 g each time, 3 times per day)
Study: 25881456
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of SG and telmisartan treatment group (telmisartan 80 mg per day, once daily and SG 5 g each time, 3 times per day)
Study: 25881456
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of SG and telmisartan treatment group
Study: 9562692
Drug: DTPa‐HB vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: DTPa‐HB vaccine administered at 2, 4, and 6 months (group A)
Study: 9562692
Drug: DTPa‐HB vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: DTPa‐HB vaccine administered at 3, 5, and 11 months (group B)
Study: 1146927
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of very low doses (20 to 40 mug per day) of estrogen with various 19-nor progestins
Study: 30844728
Drug: Beta-blocker titration
Normalized name: interferon beta-1a
DrugBank: Interferon beta-1a (DB00060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Beta-blocker titration (bisoprolol and carvedilol)
Study: 30158384
Drug: NK-104-NP (pitavastatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: NK-104-NP (pitavastatin calcium) 1 mg
Study: 30158384
Drug: NK-104-NP (pitavastatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: NK-104-NP (pitavastatin calcium) 2 mg
Study: 30158384
Drug: NK-104-NP (pitavastatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: NK-104-NP (pitavastatin calcium) 4 mg
Study: 30158384
Drug: NK-104-NP (pitavastatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: NK-104-NP (pitavastatin calcium) 8 mg
Study: 20298497
Drug: certolizumab pegol
Normalized name: Certolizumab Pegol
DrugBank: Certolizumab pegol (DB08904)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: certolizumab pegol 400 mg (week 0, 2, 4)
Study: 20298497
Drug: certolizumab pegol
Normalized name: Certolizumab Pegol
DrugBank: Certolizumab pegol (DB08904)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: certolizumab pegol 400 mg every 4 weeks until week 24
Study: 9437314
Drug: Mitomycin C
Normalized name: Mitomycin C
DrugBank: Mitomycin (DB00305)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mitomycin C (0.02 mg/ml)
Study: 9437314
Drug: Gentamicin solution
Normalized name: gentamicin Injectable Solution
DrugBank: Gentamicin (DB00798)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Gentamicin solution (0.3%)
Study: 2698568
Drug: 75 mg
Normalized name: talc 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75 mg gallopamil (slow release) twice daily
Study: 29984439
Drug: saline solution
Normalized name: Unisol 4 Saline Solution
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: saline solution pH 7.0
Study: 29984439
Drug: saline solution
Normalized name: Unisol 4 Saline Solution
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: saline solution pH 4.3
Study: 23245824
Drug: Extracorporeal shock
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Extracorporeal shock wave therapy (ESWT) given immediately after BTX-A injections
Study: 23245824
Drug: Electrical stimulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Electrical stimulation (ES) given immediately after BTX-A injections
Study: 16371497
Drug: Low level
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low level laser therapy (LLLT) at 5.4 J per point, power density 20 mW/cm2
Study: 2485053
Drug: alpha-human ANP
Approvals — FDA: no, EMA: no, PMDA: no
Description: alpha-human ANP after acute CE inhibition by enalapril (EN) 20 mg P.O., 4 h before ANP infusion
Study: 22863328
Drug: 5·0×10(6) cells
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5·0×10(6) cells per mL every 7 days
Study: 22863328
Drug: 5·0×10(6) cells
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5·0×10(6) cells per mL every 14 days
Study: 22863328
Drug: 0·5×10(6) cells
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0·5×10(6) cells per mL every 7 days
Study: 22863328
Drug: 0·5×10(6) cells
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0·5×10(6) cells per mL every 14 days
Study: 19995096
Drug: Biphasic insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Biphasic insulin aspart 30 twice daily
Study: 19995096
Drug: Insulin aspart
Normalized name: Insulin Aspart
DrugBank: Insulin aspart (DB01306)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Insulin aspart three times daily with or without NPH insulin
Study: 10480584
Drug: Extended release
Normalized name: Tylenol Extended Release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended release albuterol sulfate
Study: 7586313
Drug: 125 mg
Normalized name: niacin 125 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 125 mg intravenous amiodarone
Study: 7586313
Drug: 500 mg
Normalized name: bran 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg intravenous amiodarone
Study: 7586313
Drug: 1000 mg
Normalized name: bran 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000 mg intravenous amiodarone
Study: 7586313
Drug: All doses
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All doses of intravenous amiodarone
Study: 11026946
Drug: Couple therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Couple therapy
Study: 31666059
Drug: Generic drugs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Generic drugs awareness
Study: 31666059
Drug: Drug-related problems
Normalized name: Psoriasin Problem Skin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug-related problems awareness
Study: 27816543
Drug: Pharmaceutical assistance
Normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Pharmaceutical assistance programs (PAPs) for smoking cessation medications
Study: 21844082
Drug: n-3 polyunsaturated
Normalized name: Omega-3 (n-3) polyunsaturated fatty acids
Approvals — FDA: no, EMA: no, PMDA: no
Description: n-3 polyunsaturated fatty acids (2 g/d)
Study: 25708991
Drug: Attention bias
Normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Attention bias modification treatment (ABMT)
Study: 25708991
Drug: Attention bias
Normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Attention bias modification treatment (ABMT) delivered in clinic
Study: 25708991
Drug: Attention bias
Normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Attention bias modification treatment (ABMT) delivered at home
Study: 23917696
Drug: Celiac plexus
Normalized name: Bos taurus solar plexus preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Celiac plexus block performed first followed by pharmacotherapy (Group I)